Kornimate/medical-research-clean huggingface dataset:
ankle sprain rehabilitation with the wii balance board

Conditions: Ankle Sprain

Summary: physical activity and in particular sport is beneficial to health. nevertheless, some of these activities may create a risk of injury. ankle sprain is the most common sport related injury. sports that are causing the highest number of ankle sprains are: football (30%), handball-basketball-volleyball-rugby (24%), gymnastics sports (6%), skiing (6%), cycling (6%), athletics (4%) and contact sports (4%). a recent study in the netherlands identified a total of 1.3 million sports injuries. 47% of these patients required medical care. the total costs (direct and indirect) were assessed 84.240.000 eur per year. prospective studies demonstrated that athletes with a ankle sprain have a twofold risk of re-injury during the first year after the trauma, and in half of patients with an ankle sprain recurrence this could lead to instability or chronic pain of the ankle. the wii balance board ® is a tool that is increasingly used in the field of health. in some hospitals, therapists are beginning to use it for the rehabilitation of patients after surgery, fractures or strokes. patients are asked to complete their physical therapy session by practicing "sports" via video games such as skiing, bowling or hula hoop. currently, there are no randomized controlled studies that publish on the effectiveness of this tool. recently, a study investigated the efficacy of the wii balance board ® to improve balance, strength, joint mobility and level of physical activity. after 10 weeks of training, people an increased strength and balance was found. however, these results still require statistical confirmation. thus this objectives of this study are * to assess the efficacy of exercise training with the wii balance board ® platform * to evaluate the effectiveness of physical therapy (based on current guidelines) * to compare these two types of care (conventional physiotherapy versus wii) to a control group (non-treatment).


Eligibility criteria:
inclusion criteria: * patients with an ankle sprain (grad 1 or 2), between 18 and 65 years old, exclusion criteria: * the subjects will not be included in the study if they are under 18 years * they have other neurological or orthopedic disorders * if taking medications (other than analgesics +/- nsaids prescribed during a sprain) that may influence the measurements. * the patients with recurrent sprain of the ankle which was less than 12 months or who require surgery were also excluded.

Keywords: ankle sprain balance gait
phase 2a study to evaluate the efficacy and safety of medi9929 in adults with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: to assess the efficacy and safety of medi9929 in adult subjects with atopic dermatitis

this is a phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of medi9929 administered subcutaneously to adult subjects with moderate to severe atopic dermatitis. subjects will be randomized in a 1:1 fashion and will be stratified at screening. approximately 100 subjects are planned to be randomized at approximately 35 sites in 6 countries

Eligibility criteria:
inclusion criteria: * ad meeting hanifin and rajka criteria * age 18-75 years inclusive at screening * atopic dermatitis that affects greater than/equal to 10% body surface area * moderate to severe ad * effective birth control in line with protocol details exclusion criteria: * active dermatologic conditions which may confuse the diagnosis of atopic dermatitis * hepatitis b, c or hiv * pregnant or breastfeeding * history of anaphylaxis following any biologic therapy * history of clinically significant infections within 4 weeks prior to visit 3 * diagnosis of helminth parasitic infection within 6 months to screening * history of cancer except basal cell * receipt of any marketed or investigational biologic agent within 4 months to visit 3 * any clinically relevant abnormal finding * major surgery within 8 weeks prior to visit 1

Keywords: eczema
hearing healthcare assessment in rural communities

Conditions: Hearing Loss, Adult-Onset; Hearing Loss, Age-Related

Summary: adult hearing loss in is the third most common chronic health condition in the united states. adults living in rural areas face a higher risk of experiencing hearing loss, and more difficulty receiving testing and treatment than adults in urban settings. the goal of this clinical trial is to develop and test a community-based hearing healthcare patient navigation program in rural kentucky. the main question this study aims to answer is: -can the number of rural adults receiving diagnostic hearing tests be increased?

investigators will pilot test the rural hearing health care patient navigation program (n=500 patients from 10 rural clinics). the program will be evaluated with the following outcome: number of participants obtaining a diagnostic audiogram within past 12 months after enrollment among rural adults

Eligibility criteria:
inclusion criteria: * age 18 years or older) * able to speak, understand, and read english. exclusion criteria: -under 18

Keywords: patient navigator adult hearing screening adult hearing loss
her2 positive ctc in advanced gastric cancer

Conditions: HER2 Positive Advanced Gastric Cancer

Summary: to identify the correlation of her2 expression in tissue and peripheral ctc. to identify the her2 expression in ctcs with clinical prognosis in advanced/metastatic gastric cancer. confirm the presence of ctcs are sensitive for monitoring response to chemotherapy.


Eligibility criteria:
inclusion criteria: * having signed informed consent * age≥ 18 years old * her2 overexpression confirmed by ihc or ish (ihc 3+,or ihc2+/ish+) * histologically confirmed gastric adenocarcinoma * unresectable recurrent or metastatic disease * previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more than 6 months * measurable disease according to the recist criteria * karnofsky performance status ≥70 * life expectancy of ≥3 month * no prior radiotherapy except radiotherapy at non-target lesion of the study more than 4 weeks * alt and ast\<2.5 times uln (≤5 times uln in patients with liver metastases) * serum albumin level ≥3.0g/dl * serum akp \< 2.5 times uln * serum creatinine \<uln, and ccr \< 60ml/min * bilirubin level \< 1.5 uln * wbc\>3,000/mm3, absolute neutrophil count ≥2000/mm3, platelet\>100,000/mm3, hb\>9g/dl exclusion criteria: * previous systemic therapy for metastatic gastric cancer * surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry contraindications of nuclear magnetic resonance image such as fitment of cardiac pacemaker , nerve stimulator, or aneurysm clip, and metallic foreign body in eye ball and so on. * allergic constitution or allergic history to protium biologic product or any investigating agents. * severe heart disease or such history as recorded congestive heart failure, uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve disease, severe abnormal ecg findings, cardiac infarction , or retractable hypertension. * pregnancy or lactation period * other previous malignancy within 5 year, except non-melanoma skin cancer * legal incapacity
effect of weekly glp1 agonist treatment in "double diabetes"

Conditions: Double Diabetes

Summary: between 16% and 22% of type 1 diabetic patients present a clinical and biological profile of insulin resistance favored by a family history of type 2 diabetes or metabolic syndrome. they constitute a group of patients with "double diabetes" since they have both true type 1 diabetes and inherited insulin resistance, typical of type 2 diabetes. for several years, glp1 agonists have been successfully used in the treatment of type 2 diabetes, leading to very significant improvements in glycemic control and weight loss. because of the insulin-sensitizing power of glp1 agonists, the investigators hypothesize that they could reduce insulin resistance in patients with "double diabetes" and thus improve their glycemic control. the investigators propose to use in this study semaglutide, the most recent and most potent glp1 agonist (superiority demonstrated compared to exenatide lp and dulaglutide) and administered as a weekly subcutaneous injection (in contrast to liraglutide administered daily).


Eligibility criteria:
inclusion criteria: * person who has given written consent * patient over 18 years of age * patient with type 1 diabetes confirmed by a c-peptide below laboratory standards * age at diagnosis \< 35 years * treated with optimized insulin therapy (multi-injections or pump) for at least 1 year, having received specific therapeutic education on insulin dose adaptation. * bmi (weight/height2) ≥ 27 kg/m². * at least one of the following criteria: * family history of type 2 diabetes (parents, grandparents, uncles, aunts, brothers and sisters) * family history of obesity (bmi\>30 kg/m2) (parents, grandparents, uncles, aunts, siblings) * triglycerides \> 1.50g/l (1.7mmol/l) * hdl\< 0.5 g/l (1.29 mmol/l) in women, hdl\<0.4 g/l (1.03 mmol/l) in men * hba1c ≥ 7.5% and \< 12% in the 3 months preceding inclusion * having continuous glucose monitoring by a cgm (holter glucose monitoring) system: guardian, dexcom or free style libre * for women of childbearing age: using an effective method of contraception until 2 months after the end of treatment. effective contraception includes: hormonal contraception, intrauterine device, bilateral tubal occlusion, vasectomy and sexual abstinence exclusion criteria: * person not affiliated to national health insurance * pregnant, parturient or breastfeeding woman * hba1c ≥12% in the 3 months preceding inclusion. * uncontrolled and potentially unstable diabetic retinopathy or maculopathy, confirmed by a fundus examination performed in the 6 months preceding the selection * person under a measure of legal protection (curatorship, guardianship) * renal insufficiency (gfr\<30 ml/mn) * hepatic insufficiency (inr\> 1.5) * bmi \>40 kg/m². * history of bariatric surgery * history of pancreatitis * allergy to the active substance or to one of the excipients of ozempic®. * patients treated with glp1 agonists or oral antidiabetics in the month preceding month prior to inclusion
effect of covid-19 infection on obstertric complications and maternal outcomes

Conditions: COVID-19; Infection; Obstetric Complication; Maternal Outcomes

Summary: this study aimed to evaluate the effect of covid-19 infection on obstetric complications and maternal outcomes.

during the sars-cov-2 pandemic, pregnant women were reported to have a higher susceptibility to covid-19 infection. pregnant women who tested positive for sars-cov-2 are at higher risk of a severe form of covid-19, associated with higher rates of intensive care unit (icu) admission and increased needs for respiratory support, compared to the age-matched non-pregnant population. women infected during pregnancy also have an increased risk of adverse pregnancy outcomes including preterm-birth, with a significant proportion secondary to iatrogenic preterm birth due to maternal illness. infection with sars-cov-2 during pregnancy has also been reported to be associated with a higher risk of stillbirth directly or indirectly caused by the virus. infected pregnant patients tended to present asymptomatically with pre-delta and omicron variants, and symptomatically with delta variant. a previous systematic review suggested that people who are pregnant did not have an increased risk of sars-cov-2 infection or symptomatic covid-19, but they were at risk of severe covid-19 compared with those who were not pregnant.

Eligibility criteria:
inclusion criteria: * age from 18 to 40 years. * pregnant women with covid-19 infection diagnosed either by pcr or rapid test. exclusion criteria: • patients vaccinated for covid-19 before or during the current pregnancy.
efficacy of two types of non-invasive erector spinae muscle taut band therapy in university students with low back pain

Conditions: Low Back Pain; Trigger Point Pain, Myofascial

Summary: non-specific low back pain can be caused by the presence of active trigger points in the muscles of the lumbopelvic region. trigger points are defined as hypersensitive points within a taut band of a musculoskeletal system that cause pain during contraction, stretching, or stimulation of said muscle. if these points are active, they can trigger referred pain, local tenderness, and vegetative responses. there is scientific evidence of the improvement of the treatment of these points through non-invasive manual techniques. the objective of this study will be to determine the effect of strain counterstrain and myofascial induction techniques in subjects with low back pain secondary to the presence of active trigger points in the lumbopelvic region. hyperexcitable myofascial trigger points located within a taut band of skeletal muscle or fascia cause referred pain, local tenderness, and autonomic changes. the scientific data refer to an immediate improvement in the symptoms of these active points treated with manual therapy. based on these factors, the objective of the study is to determine the effect of the combined therapy of the strain counterstrain technique and myofascial induction in participants with the presence of an active trigger point in the erector spinae muscle.

the treatment will last a total of 15 minutes accompanied by a baseline assessment and after 10 minutes of the intervention in 2 experimental groups and a placebo group, of no-pain positioning. in addition to basic indices and scales of low back pain and disability caused by low back pain, it is intended to measure flexibility, range of motion, proprioception and cognition through software with sensors of the latest technology when representing reliable results in differences between techniques.

Eligibility criteria:
inclusion criteria: * presence of low back pain * presence of active trigger point in the erector spinae as described by lawrence h. jones exclusion criteria: * participants who present dizziness, vertigo; * previous or scheduled surgeries in the lumbar spine and/or lower extremities; * suspicion of serious fractures or pathologies (tumor, inflammation, infection, rheumatological disorder, systemic disease, presence of fever); * diagnosis of radiculopathy or neuropathy; * structural deformity in the spine; spondyloarthropathy, disabling pain and physical disability; * use of pain relievers or anti-inflammatory drugs in the last 48 hours; * neurological or psychiatric disorder; * presence or suspicion of pregnancy

Keywords: physiotherapy rehabilitation treatment active trigger point
antiretroviral adherence and drug-level monitoring

Conditions: HIV Infections; AIDS; Antiretroviral Therapy, Highly Active; Adherence, Medication; Drug-level Monitoring

Summary: this observational study aims to investigate medication adherence and drug-level monitoring of antiretroviral agents in a cohort of people living with hiv in indonesia. the study is conducted in outpatients receiving tenofovir-based regimens in a university medical centre.

optimal adherence is critical to achieve and sustain viral suppression. currently, there is no gold standard measure of antiretroviral adherence and exposure in clinical practice. recent studies have evaluated the use of emerging biological matrices such as dried blood spots, urine, and saliva as means of objective adherence measures. for drug-level monitoring, tenofovir is selected as a drug of interest and thus only people receiving tenofovir disoproxil fumarate-based regimens will be monitored. some studies have reported that higher plasma trough concentrations of tenofovir were associated with renal toxicity. therefore, this project aims to measure level of adherence and tenofovir concentrations in plasma and emerging matrices among people living with hiv in indonesia. primary outcome is adherence to art that will be measured using multi methods, including self-report questionnaire, pill counting, electronic monitoring, and drug-level testing. secondary outcomes include tenofovir concentrations in plasma, urine, saliva, and dried blood spots and clinical outcomes (viral load and cd4 count). assays for measuring tenofovir concentrations will be developed using high-performance liquid chromatography-tandem mass spectrometry. concentrations derived from dried blood spots, saliva, and urine will be compared to plasma concentrations. pharmacokinetic models will be used to interpret drug-level monitoring. the association of adherence measures as well as drug concentrations and clinical outcomes will be examined.

Eligibility criteria:
inclusion criteria: * adults with hiv who have been receiving antiretroviral therapy containing tenofovir-based regimens for at least six months exclusion criteria: * pregnant and breastfeeding women, people with kidney failure, undergoing hemodialysis or peritoneal dialysis, uncontrolled diabetes, uncontrolled hypertension, and hypersensitivity to tenofovir

Keywords: adherence adult pharmacokinetics tenofovir viral load
e-nature vr: evaluation of the impact of virtual reality during breast biopsy

Conditions: Pain; Breast Pain

Summary: randomized clinical trial about the evaluation of the impact of the virtual reality intervention on the experience of pain, physical and psychological discomfort, well-being and anxiety of women during breast biopsy use of nature virtual reality video.

breast biopsy is one of the main tests for the diagnosis of cancer, which generates emotional distress and can be a painful procedure. distraction has considerable efficacy among mild psychological methods for reducing pain perception. virtual reality is the most advanced technology of distraction, with the highest level of immersion in virtual worlds and effective results as a non-pharmacological measure in pain perception. however, audiovisual resources related to nature have not yet been investigated in this clinical setting. this clinical trial aims to verify the impact of the virtual reality intervention on the experience of pain, physical and psychological discomfort, well-being and anxiety of women during breast biopsy; its influence on the time of the examination; the degree of recommendation of the intervention; and if the connection with nature interferes in the results obtained on the studied variables. the immersive reality intervention will be provided during the breast biopsy and the variables will be evaluated using likert-type scales and pain using the analog virtual scale. our study hypothesis is that this intervention reduce the perception of pain / discomfort during the biopsy by connecting with nature, reducing anxiety, exam time, and increasing the sense of well-being.

Eligibility criteria:
inclusion criteria: * voluntary participation; * signed in the informed consent form; * patients with clinical conditions and preserved communication function, in other words, lucid patients; * patients in breast biopsy procedure. exclusion criteria: * blind patients; * patients without the capacity for judgment, in other words, with dementia; * patients who have their clinical condition changed during the breast biopsy. patients with history of nauseas vertigo and labyrinthitis

Keywords: pain virtual reality breast biopsy environmental health patient comfort complementary therapies nurse care
prospective evaluation of the long-term effectiveness of the femtosecond laser-assisted arcuate incisions

Conditions: Astigmatism

Summary: this clinical study is an open, controlled, prospective, single center, single-surgeon, post-market-clinical-follow-up study to evaluate the long-term (18 months) effectiveness of the femtolaser-assisted astigmatic keratotomy.

the purpose of this prospective post-market-clinical-follow-up study is to address the long-term effectiveness of arcuate incisions, in eyes after victus femtosecond laser-assisted astigmatic keratotomy. this study will be conducted at gemini eye clinic in zlin, czech republic by dr. pavel stodulka who will examine up to 100 eyes who previously received victus femtolaser-assisted arcuate incisions treatment. patients will be recruited according to the study inclusion/exclusion criteria.

Eligibility criteria:
inclusion criteria: * clear corneal media * patients must be at least 40 years of age * victus™ femtosecond laser-assisted arcuate incisions surgery * preoperative keratometric astigmatism: ≥ 1.0d and ≤ 3d * patients must have read, understood the patient information and signed the informed consent form * patients are willing and able to return for follow-up examinations exclusion criteria: * corneal disease or pathology, such as corneal scaring * subjects with a poorly dilating pupil or other defect of the pupil that prevents the iris from adequate retraction peripherally * lens/zonular instability such as, but not restricted to, marfan's syndrome, pseudoexfoliation syndrome, etc. * manifest glaucoma * known sensitivity to planned concomitant medications * patients regularly taking medicines that could influence the result of the treatment respectively the vision * patients with disorders of the ocular muscle, such as nystagmus or strabismus * patients with keratoconus, keratectasia or other irregular cornea changes * patients with connective tissue weakness * subjects who are immune compromised or carrying diagnosis of connective tissue disease, clinically significant atopic disease, insulin dependent diabetes mellitus, autoimmune diseases, ocular herpes zoster or simplex, endocrine diseases, lupus, rheumatoid arthritis, collagenosis and other acute or chronic illnesses that will increase the risk to the subject or confound the outcomes of this study. * abnormal examination results from slit lamp, fundus examination or iolmaster; age related changes are acceptable * patients with eye diseases which decreases the visual acuity such as macular degeneration, macular edema, proliferative diabetic retinopathy * abnormal examination results from topography, age related changes are acceptable * patients who are pregnant or nursing * patients with concentration disorders, epilepsy and other complicating diseases * patients who are participating in another clinical study 30 days before

Keywords: astigmatism, arcuate incisions, astigmatic keratotomy